---
title: "Gilead Sciences: Strong Q4 Results And Huge Progress In HIV"
date: "2025-02-12 16:25:29"
summary: "Gilead HQ in Foster City, CA Michael Vi  Last June, I highlighted Gilead Sciences (NASDAQ:GILD), rating the company a strong buy after positive Phase 3 results for lenacapavir. On Tuesday, Gilead reported strong Q4 results, beating"
categories:
  - "seekalpha_articles"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha_articles"
menu: ""
thumbnail: "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209171665/image_1209171665.jpg"
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

![Gilead sign at headquarters. Gilead Sciences announced plans to test a treatment for COVID-19, disease caused by growing coronavirus outbreak](https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1209171665/image_1209171665.jpg?io=getty-c-w750)



Gilead HQ in Foster City, CA

Michael Vi





Last June, I highlighted **Gilead Sciences** (NASDAQ:[GILD](https://seekingalpha.com/symbol/GILD "Gilead Sciences, Inc.")), rating the company a strong buy after [positive Phase 3](https://investors.gilead.com/news/news-details/2024/Gileads-Twice-Yearly-Lenacapavir-Demonstrated-100-Efficacy-and-Superiority-to-Daily-Truvada-for-HIV-Prevention/default.aspx) results for lenacapavir. On Tuesday, Gilead reported strong [Q4 results](https://s29.q4cdn.com/585078350/files/doc_financials/2024/q4/v5/GILD-Q424-Earnings-Press-Release-11-February-2025.pdf), beating

[seekalpha_articles](https://seekingalpha.com/article/4757340-gilead-sciences-strong-q4-earnings-huge-progress-hiv)
